Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical study is to learn more about the timing of tics (sudden, fast movements and sounds that people do and make without meaning to) in people who have multiple tics that have been going on for more than one year. The main questions it aims to answer are: 1. See whether a tic's timing is related to other characteristics of the tic, like how long it has been happening and how well the person can control/stop that tic 2. See whether the timing of a tic can tell us how well the person can control/stop that tic 3. See whether tic treatment changes the timing of tics, and if the timing of a tic has anything to do with how well treatment will work to stop it Participants will meet with a study researcher to learn more about the study, ask questions, and decide whether or not they would like to be involved. If they decide to do the study, they will meet with the researcher 6 times: 1. During the first visit, the study researcher will ask questions about the participant's life, tics, and other psychological symptoms. The researcher will watch the participant's tics for 10 minutes. The participant will do a computer task where they follow instructions to tic or not tic. 2. During the second visit, the study researcher will treat one of the participant's tics. 3. During the third visit, the study researcher will treat another one of the participant's tics. 4. During the fourth visit, the study researcher will treat another one of the participant's tics. 5. During the fifth visit, the study researcher will treat another one of the participant's tics. 6. During the sixth visit, the study researcher will ask questions about the participant's tics and other psychological symptoms. The participant will do a computer task where they follow instructions to tic or not tic.


Clinical Trial Description

Interested participants will attend an initial phone call or virtual meeting to explain the study, answer any study-related questions, and screen for eligibility. The consent and assent process will take place online via secure videoconference. Parents will be instructed ahead of time to be in a secure location with their child. Study personnel will explain the study, review the parental permission/consent and assent forms, and answer study-related questions. Participants will be asked to consider and discuss study participation with the study personnel out of the virtual room to encourage the participants to discuss his/her/their willingness to participate and any concerns that they may have. Children will also be asked to provide verbal assent/willingness to participate during this process. If the child is unsure at that time, he/she/they will be encouraged to ask questions and for the parents to reach out again in the future if the child would like to provide verbal assent or decline to participate. All study visits will take place online via secure videoconference and be video recorded and later coded for reliability and procedural fidelity. Participation will involve six visits that comprise three phases: 1) a pre-treatment (baseline) assessment; 2) four sessions of standard Habit Reversal Training (HRT) for tics, and 3) a post-treatment assessment. At the beginning of the HRT visits, participants will also undergo a direct observation of their tics. At the beginning of the baseline and post-assessment visits, participants will also undergo a standard reinforced tic suppression task (RTST) consisting of three repeated alterations (ABABAB) of a free-to-tic (FTT; A condition) and a differential reinforcement for tic suppression condition (DRO; B condition). Participants who withdraw from the study before their post-treatment assessment will be asked to attend a final study visit to document their reason for withdrawal and complete the debriefing process, however, this visit will be voluntary. All measures aside from the demographics form and between-session activities form are standardized. Study Visit #1 (Phase 1: Pre-Treatment [Baseline] Assessment) Following the informed consent/assent process, families will complete a clinical interview with trained study personnel. The clinical interview will confirm that the participant meets the criteria for the study and collect information for subsequent study procedures. Then, the child participant will engage in the RTST. Overall, the first study visit will take approximately 2 hours to complete. Clinical Interview and Assessment: The clinical interview will include general questions regarding the child's tic symptoms and other psychological/behavioral symptoms/disorders, overall functioning, and family medical history. The diagnostic assessment will consist of the Yale Global Tic Severity Scale (YGTSS) to determine overall tic severity and obtain a list of operationally-defined tics; the Parent Tic Questionnaire (PTQ) to determine individual tic severity; and the Individualized Premonitory Urge for Tics Scale (I-PUTS) to characterize general and individual premonitory urge severity of tics, respectively. The clinical interview will also include a 10-minute tic observation period. History and Demographics Form: Parents will complete a demographic form collecting data about age, gender, race/ethnicity, occupational/educational history, psychiatric and medical status/history, treatment history and medication status, and other relevant psychosocial factors. Tic Observation: The child will be directly observed for 10 minutes with the study personnel off-camera to ensure that they meet the criteria for enrollment (i.e., display at least four different tics per minute, on average). Reinforced Tic Suppression Task (RTST) The RTST will be comprised of repeated sessions of two experimental conditions: FTT (Condition A) and DRO (Condition B). Each condition will be repeated three times for a total of six sessions (ABABAB). Each session will last 5 minutes, and the order of sessions will be identical across all participants and administrations. During each session, participants will be seated facing their computer's video camera. The child will be provided with specific instructions for the condition and an investigator will monitor the child's performance covertly (via video) to ensure procedural adherence during the session. A manipulation check will be conducted immediately after each session, during which the participant will be asked to repeat the instructions that they were given for the recently completed session and rate how hard they tried to suppress their tics and how well they thought they suppressed their tics. For the DRO conditions, participants will also be asked how they earned tokens. FTT condition 1A. The purpose of this condition is to establish tic rate in the absence of reinforcement and will serve as a comparison for the DRO condition described below. In the FTT condition, participants will be told that they should feel free to tic as little or as much as they need to, but to avoid suppressing their tics. No reinforcement will be delivered during this condition. DRO condition 1B. The purpose of this condition is to examine the effects of differential reinforcement on tic frequency. Prior to the start of the condition, participants will be instructed to suppress their tics and will be informed that they will earn a token for every 10-second interval (i.e., trial) in which they do not display any tics. The experimenter will monitor tics and deliver reinforcers by displaying a digital image of a token on the child's screen according to a resetting DRO 10-s schedule, wherein a token will be delivered immediately after each trial during which no tics are observed. If one or more tics are observed during a trial, reinforcement will be withheld, and the count-down timer will be reset. FTT conditions 2A and 3A. The third and fifth sessions will involve repetitions of the FTT 1A condition described above. DRO conditions 2B and 3B. The fourth and sixth sessions will involve repetitions of the DRO 1B condition described above. Study Visits #2-5 (Phase 2: Habit Reversal Training [HRT]) Participants will engage in four HRT sessions delivered across five weeks via secure videoconference. Each session of HRT will be focused on a single, target tic. The target tic for each HRT session will be predetermined following the baseline assessment and before the first session of HRT. The target tics will be randomly chosen from a subset of a list of operationally defined tics that are hierarchically arranged by frequency based on the results obtained from the YGTSS and PTQ administered at the baseline assessment. If, during the study, participants report newly onset tics, they will be documented but will not be targeted in treatment. To assess between-session differences across participants, HRT sessions 2-4 will begin with participants answering questions about between-session HRT practice. Next, a 10-minute direct observation of tics will be conducted to determine the resting tic rate. The child will be instructed to feel free to tic as little or as much as they need but to avoid suppressing their tics. Participants will then engage in brief HRT for a single, target tic consistent with manualized procedures. HRT will begin with awareness training, including developing a detailed description of the target tic and practicing "catching" the target tic before it occurs. Participants will engage in this exercise for 10 minutes or until they can successfully catch their target tic at least 80% of the time that it occurs within a five-minute period, whichever occurs first. The participant will then engage in competing response (CR) training, including identifying a behavior that can be observed and is incompatible with the target tic. Participants will be instructed to engage in that behavior when they feel the urge associated with their target tic for one minute, or until the urge subsides, whichever is longer. Participants will be verbally prompted by the therapist to engage in the CR whenever the target tic is observed. Participants will practice using the selected CR to suppress their target tic for 10 minutes or until they can use it effectively at least 80% of the time over a five-minute period, whichever occurs first. The participant will be instructed to engage in 15 minutes of CR practice for their target tic(s) each day before the next treatment session. Parents of participants will be instructed to partake in the daily CR practice session with their child by prompting and verbally reinforcing the use of the CR. Overall, the approximate duration of treatment sessions will be 45 to 60 minutes. Study Visit #6 (Phase 3: Post-Treatment Assessment) The post-treatment assessment will occur within one week of the last HRT session. To assess between-session differences across participants, the post-treatment assessment will begin with participants answering a series of questions regarding between-session practice and adverse events. Next, participants will engage in the RTST. Participants will then complete a diagnostic assessment with trained study personnel consisting of the YGTSS, PTQ, and I-PUTS. Participation will be considered complete at this point. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06385535
Study type Interventional
Source University of Utah
Contact Kirsten Bootes, MS
Phone 801-585-7114
Email kirsten.bootes@psych.utah.edu
Status Recruiting
Phase N/A
Start date April 4, 2024
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04851678 - Longitudinal Impact of Stressors in Adults With Tourette Syndrome
Completed NCT02605902 - Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders N/A
Completed NCT04007913 - Incorporating teleCBIT Into a Hospital-Based Tic Program N/A
Completed NCT02900144 - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT) N/A
Completed NCT02256475 - Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome Phase 1
Completed NCT02216474 - Brain Stimulation in Movement Disorders N/A
Completed NCT01329198 - Brain Stimulation for the Treatment of Tourette Syndrome N/A
Terminated NCT00952601 - Pilot Study of the Modified Atkins Diet for Tourette Syndrome Phase 1
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00206323 - A Randomized, Placebo-controlled, Tourette Syndrome Study. Phase 3
Completed NCT00004376 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Phase 3
Completed NCT04498364 - Extinction Learning in Adults With Tourette Syndrome N/A
Completed NCT00755339 - Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
Completed NCT03325010 - Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT01719523 - Open-Trial of EPI-743 for Adults With Tourette Syndrome Phase 1
Completed NCT01702077 - Neurofeedback for Tourette Syndrome N/A
Completed NCT00231985 - Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder Phase 2
Completed NCT00206336 - An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Phase 3
Terminated NCT03732534 - Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome Phase 2